Condition
Preeclampsia With Severe Features
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
Termination Rate
50.0%
2 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 4 (2)
Trial Status
Completed2
Terminated2
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05096728CompletedPrimary
Nifedipine Dosing Daily vs Twice a Day for Pre-eclampsia With Severe Features (NOPPI)
NCT04474704Not ApplicableCompletedPrimary
Use of Cheetah® Cardiac Monitoring System to Guide Discontinuation of Magnesium Sulfate in Women With Severe Preeclampsia
NCT03872336Phase 4TerminatedPrimary
Acute Labetalol Use in Preeclampsia
NCT03877692Phase 4TerminatedPrimary
Acute Control of Chronic Hypertension
Showing all 4 trials